Phase I and pharmacokinetic study of veliparib, a PARP inhibitor, and pegylated liposomal doxorubicin (PLD) in recurrent gynecologic cancer and triple negative breast cancer with long-term follow-up
Bhavana Pothuri, Allison L. Brodsky, Joseph A. Sparano, Stephanie V. Blank, Mimi Kim, Dawn L. Hershman, Amy Tiersten, Brian F. Kiesel, Jan H. Beumer, Leonard Liebes, Franco M. Muggia
Topics & Concepts
VeliparibMedicinePARP inhibitorOlaparibInternal medicineOncologyCancerBRCA mutationDoxorubicinTriple-negative breast cancerOvarian cancerBreast cancerChemotherapyPharmacologyCancer researchPoly ADP ribose polymeraseChemistryPolymeraseBiochemistryGenePARP inhibition in cancer therapyOvarian cancer diagnosis and treatmentAdvanced Breast Cancer Therapies